Trial · NCT07285239
Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma
NCT07285239, Phase 3, Recruiting, PrECOG, LLC.
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma. Trials, record NCT07285239. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07285239
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma
- NCT number
- NCT07285239
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 500 participants, estimated
- Lead sponsor
- PrECOG, LLC.
- Conditions
- Multiple Myeloma
- Interventions
- Arm A: Belantamab Mafodotin, Arm B: Daratumumab Hyaluronidase, Bortezomib, Lenalidomide, Dexamethasone
- First posted
- 2025-12-16
- Last updated
- 2026-11-12
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | MRD Negative Status | Up to 86 months | MRD negative status, defined as achieving MRD negativity at 10-5 sensitivity threshold assessed by NGS at least once during the time of confirmed CR or better response per IMWG criteria by Independent Review Committee (IRC); MRD negativity is determined by the Adaptive Biotechnologies clonoSEQ® assay result |
| Primary | Progression-Free Survival (PFS) | Up to 86 months | PFS, defined as the time from the date of randomization to the date of first documented disease progression per IMWG criteria by IRC or death from any cause in the absence of progression, whichever occurs first |
| Secondary | Overall Survival (OS) | Up to 86 months | OS, defined as the time from the date of randomization until the date of death due to any cause |
| Secondary | Best Response of Complete Response (CR) | Up to 86 months | Defined as confirmed CR or better per IMWG criteria by IRC |
| Secondary | Best Response of Very Good Partial Response (VGPR) | Up to 86 months | Defined as confirmed VGPR, CR or better per IMWG criteria by IRC |
| Secondary | Overall Response Rate (ORR) | Up to 86 months | Defined as confirmed PR, VGPR, CR or better per IMWG criteria by IRC |
| Secondary | Duration of Response (DoR) | Up to 86 months | DoR, defined as the time from first documented evidence of partial response (PR) or better until progression (PD) or death due to PD (among participants who achieve confirmed PR or better) by IRC |
| Secondary | MRD Negative Status at 12-Month | Up to 86 months | Defined as achieving MRD negativity at 10-5 sensitivity threshold assessed by NGS in participants achieving confirmed CR or better response per IMWG criteria by Independent Review Committee (IRC) after 12 (+/-3) months; MRD negativity is determined by the Adaptive Biotechnologies clonoSEQ® assay result |
| Secondary | Sustained MRD (sMRD) Negative Status | Up to 86 months | sMRD, defined as achieving MRD negative status at 10-5 sensitivity threshold assessed by NGS at least twice, a minimum of 1 year apart and with no MRD positive result in between, during the time of confirmed CR or better response per IMWG criteria by IRC |
| Secondary | Adverse Events (AEs) | While on study treatment and up to 70 days after the last dose of study medication | Worst Grade 3 or Higher Treatment-Related Non-Hematologic and Overall Toxicity based on CTCAE v6.0 |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07285239
GET https://conductscience.org/api/trials/v1/NCT07285239/registered